UroGen Pharma Shares Are Trading Higher After the Company on Thursday Announced an 82.3% 12-month Duration of Response in Its Phase 3 ENVISION Trial for UGN-102, Achieving a 79.6% Complete Response Rate at Three Months. On Friday, Multiple Analysts...
UroGen Pharma Shares Are Trading Higher After the Company on Thursday Announced an 82.3% 12-month Duration of Response in Its Phase 3 ENVISION Trial for UGN-102, Achieving a 79.6% Complete Response Rate at Three Months. On Friday, Multiple Analysts...
UroGen Pharma股票上漲，因公司週四宣佈其Phase 3 ENVISION試驗中UGN-102的12個月持續響應達到82.3％，在3個月內達到79.6％的完全響應率。星期五，多家分析師提高了其目標價格。
UroGen Pharma Shares Are Trading Higher After the Company on Thursday Announced an 82.3% 12-month Duration of Response in Its Phase 3 ENVISION Trial for UGN-102, Achieving a 79.6% Complete Response Rate at Three Months. On Friday, Multiple Analysts Raised Their Price Targets.
UroGen Pharma股票交易走高，因爲該公司在週四宣佈，其UGN-102藥物在第三階段ENVISION試驗中呈現出82.3％在12個月內的有效持續期，並在三個月內實現了79.6％的完全緩解率。週五，多家分析師提高了其價格目標。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。